Australian experience of a modified schedule of FOLFOX with high activity and tolerability and improved convenience in untreated metastatic colorectal cancer patients

Abstract

This study determined the efficacy and safety of a modified FOLFOX regimen that improved patient convenience without compromising oxaliplatin dose intensity. A total of 62 patients with previously untreated metastatic colorectal cancer were enrolled to receive, entirely as outpatients, 2-weekly cycles of oxaliplatin 100 mg m-2 i.v. over 2 h, together with leucovorin 400 mg m-2 over 2h, 5-fluorouracil (5-FU) 400 mg m -2 bolus, followed by a 46-h infusion of 5-FU at 2.4 g m -2. Treatment was given until progression or unmanageable toxicity. In all, 61 patients received ≥ one oxaliplatin dose and a median of 11 treatment cycles (range 1-20 cycles); 22 (36%) reported grade 3/4 neutropenia and 13..